The global osteoarthritis injectables market size is anticipated to reach USD 11.42 billion by 2030, exhibiting a CAGR of 6.82% from 2024 to 2030. The market is experiencing growth, influenced by several key factors. Women aged 50 to 60 are more susceptible to developing hand and knee osteoarthritis (OA) compared to men, due to hormonal changes and musculoskeletal differences, as highlighted by Arthritis-health data from January 2021. Additionally, obesity rates, higher among women according to the National Institutes of Health, further increase the risk. In the U.S. alone, it is projected that the number of osteoarthritis patients will reach 70 million by 2040.
The growing geriatric population is a significant driver for market expansion. An NCBI report from May 2023 predicts that the combination of an aging population and obesity will more than double the number of osteoarthritis patients to 67 million by 2030. The majority of cases are expected to occur in individuals aged 65 and above, with 45% of current osteoarthritis patients falling into this age group, according to an OAAA study supported by the CDC in March 2024. This demographic shift impacts productivity, reducing work efficiency and increasing the disease burden.
Research and development activities are also boosting the osteoarthritis injectables market growth, with pharmaceutical companies and research institutes focusing on the development of novel drugs for OA management. BioSenic's announcement in January 2024 regarding the phase 3 study of JTA-004, an innovative treatment for knee OA, demonstrates the industry's commitment to advancing treatment options. Academic and research institutes are also actively involved in developing novel therapies. For instance, a GP130 investigational drug, reported in March 2023, shows promise in managing inflammation and pain. Additionally, Kolon TissueGene, Inc.'s Phase 2 clinical trial for TG-C in hip OA aims to evaluate pain and quality-of-life improvements.
The adoption of oral drugs, surgery, and home remedies such as gin-soaked raisins or wearing copper bracelets for the treatment of OA is expected to adversely affect market growth. The adoption of oral and topical treatment drugs such as analgesics, NSAIDs, and corticosteroids, is increasing due to the patient-centric approach and ease of use. Moreover, increase in research activities to develop novel oral drugs to manage inflammation and pain due to OA is anticipated to hinder the market expansion of OA injectable drugs in the coming years. For instance, in February 2022, Medivir AB published the post-hoc analysis of a randomized phase 2a clinical trial of MIV-711 and its symptomatic and structural benefits for pain management of OA. MIV-711 is an orally administered drug targeting both bone resorption and cartilage degradation.
This product will be delivered within 2 business days.
The growing geriatric population is a significant driver for market expansion. An NCBI report from May 2023 predicts that the combination of an aging population and obesity will more than double the number of osteoarthritis patients to 67 million by 2030. The majority of cases are expected to occur in individuals aged 65 and above, with 45% of current osteoarthritis patients falling into this age group, according to an OAAA study supported by the CDC in March 2024. This demographic shift impacts productivity, reducing work efficiency and increasing the disease burden.
Research and development activities are also boosting the osteoarthritis injectables market growth, with pharmaceutical companies and research institutes focusing on the development of novel drugs for OA management. BioSenic's announcement in January 2024 regarding the phase 3 study of JTA-004, an innovative treatment for knee OA, demonstrates the industry's commitment to advancing treatment options. Academic and research institutes are also actively involved in developing novel therapies. For instance, a GP130 investigational drug, reported in March 2023, shows promise in managing inflammation and pain. Additionally, Kolon TissueGene, Inc.'s Phase 2 clinical trial for TG-C in hip OA aims to evaluate pain and quality-of-life improvements.
The adoption of oral drugs, surgery, and home remedies such as gin-soaked raisins or wearing copper bracelets for the treatment of OA is expected to adversely affect market growth. The adoption of oral and topical treatment drugs such as analgesics, NSAIDs, and corticosteroids, is increasing due to the patient-centric approach and ease of use. Moreover, increase in research activities to develop novel oral drugs to manage inflammation and pain due to OA is anticipated to hinder the market expansion of OA injectable drugs in the coming years. For instance, in February 2022, Medivir AB published the post-hoc analysis of a randomized phase 2a clinical trial of MIV-711 and its symptomatic and structural benefits for pain management of OA. MIV-711 is an orally administered drug targeting both bone resorption and cartilage degradation.
Osteoarthritis Injectables Market Report Highlights
- Hyaluronic Acid (HA) injections segment dominated the market in 2023, owing to its high prescription rate in OA.
- Knee osteoarthritis segment dominated the market in 2023. Knee OA is a prevalent condition particularly affecting older individuals, with the U.S. witnessing it as the second leading cause of incapacity among men aged 50 years and above.
- Hospital pharmacies segment dominated the market in 2023. Hospital pharmacies play a pivotal role in osteoarthritis management, owing to factors such as higher number of treatments performed in the hospital setting.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Osteoarthritis Injectables Market Variables, Trends & Scope
Chapter 4. Global Osteoarthritis Injectables Market: Injection Type Estimates & Trend Analysis
Chapter 5. Global Osteoarthritis Injectables Market: Anatomy Estimates & Trend Analysis
Chapter 6. Global Osteoarthritis Injectables Market: End-use Estimates & Trend Analysis
Chapter 7. Global Osteoarthritis Injectables Market: Regional Estimates & Trend Analysis by
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Anika Therapeutics, Inc.
- Bioventus.
- Ferring Pharmaceuticals Inc.
- Sanofi S.A.
- Flexion Therapeutics, Inc.
- Zimmer Biomet
- Arthrex, Inc.
- Royal Biologics
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | June 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 7.23 Billion |
| Forecasted Market Value ( USD | $ 11.42 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
